
COVID-19 Ambulatory Anticoagulation Management Workflow and Resources



Appendix A – Considerations for Continuation of Anticoagulation Therapy During COVID-19 Pandemic

- Indication for anticoagulation therapy
- Duration of anticoagulation therapy
- Patient's bleeding risk
- Adherence to anticoagulant therapy and lab monitoring
- Availability of lab monitoring
- Patient's risk for exposure and risk factors for severe illness from COVID-19

Appendix B – DOAC Therapy Considerations						
Contraindications to DOACs	Cautions to DOACs					
 Mechanical heart valves Triple positive antiphospholipid syndrome Severe renal impairment (see DOAC specific dosing below) Moderate or severe hepatic impairment Active pathological bleeding Active malignancy Pregnant or breastfeeding Concomitant use of strong inducers or inhibitors of CYP3A4 or p-glycoprotein (ketoconazole, itraconazole, ritonavir, clarithromycin, rifampin) 	 Previous history of failed DOAC therapy DOACs not studied extensively in patients who have failed therapeutic anticoagulation, those with unusual sites of thrombosis (e.g., cerebral, splanchnic), or those with extensive GI surgeries The efficacy of DOACs in patients with antiphospholipid antibody syndrome, strong heritable thrombophilias, or heparin-induced thrombocytopenia (HIT) is uncertain Patients with history of head trauma Patients on concurrent NSAID therapy 					

Medication	Indication	Renal Function CrCl (mL/min)	Dosing		Conversion Considerations
	Non-Valvular Atrial Fibrillation	No risk factors	5 mg twice daily	•	Discontinue warfarin and start
		Any two factors:	2.5 mg twice daily		when INR < 2.0
		SCr ≥ 1.5mg/dL, age ≥80,		٠	Discontinue LMWH and start at
		weight ≤ 60kg			next scheduled dosing time of
apixaban	VTE (DVT/PE) Treatment	All patients CrCl <u>></u> 25 mL/min and	10 mg twice daily x 7 days,		LMWH
(Eliquis)			followed by 5 mg twice daily for		
		SCr <u><</u> 2.5 mg/dL	6 months		
	VTE (DVT/PE) Reduction in Risk of Recurrence	All patients	2.5 mg twice daily (following 6		
			months of initial therapy)		
	Non-Valvular Atrial Fibrillation	>30	150 mg twice daily	•	Discontinue warfarin and start
		15-30	75 mg twice daily		when INR < 2.0
dabigatran		<15 and HD	Avoid use	•	Discontinue LMWH and start ≤
(Pradaxa)	VTE (DVT/PE) Treatment VTE (DVT/PE) Reduction in Risk of Recurrence	> 30	150 mg twice daily after 5-10		2 hours prior to the next scheduled dose of LMWH
(days of parenteral		
			anticoagulation	-	
		< 30	Avoid use		
	Non-Valvular Atrial Fibrillation	>95	Avoid use	•	Discontinue warfarin and start
		51-95	60mg once daily		when INR ≤ 2.5 Discontinue LMWH and start at next scheduled dosing time of LMWH
		15-50	30 mg once daily		
Edoxaban		<15	Avoid use		
(Savaysa)	VTE (DVT/PE) Treatment (following 5 to 10 days of initial parenteral anticoagulant)	>50	60mg once daily		
(0010)00)		15-50, wt<60kg,	30mg once daily		
		concomitant P-gp			
		inhibitors			
		<15	Avoid use		
	Non-Valvular Atrial	> 50	20 mg once daily	•	Discontinue warfarin and start
	Fibrillation	<u><</u> 50	15 mg once daily	 when INR < 3.0 Discontinue LMWH and start ≤ 2 hours prior to the next scheduled dose of LMWH 	
	VTE (DVT/PE) Treatment	<u>></u> 15	15 mg twice daily x 21 days,		2 hours prior to the next
rivaroxaban (Xarelto)			followed by 20 mg once daily		
		< 15	Avoid use		
	VTE (DVT/PE) Reduction in Risk of Recurrence	<u>≥</u> 15	10 mg daily (following 6 months of initial therapy)		
		< 15	Avoid use		

Appendix C – Home INR Monitoring

Insurance Coverage

- Medicare Covered by Part B for up to 4 tests/month
- Private Insurance Covered by many private insurances, individual coverage depends on plan
- Medicaid Not covered
- Self-pay available

Eligibility Criteria

- On warfarin for 90 days and plan to take it for 1 year or more
- Be physically capable of performing a test or have a caregiver that can assist
- Demonstrate the correct use of the home INR monitor after training

Covered Indications

- Mechanical heart valve
- Atrial fibrillation
- Venous thromboembolism (DVT or PE)
- Hypercoagulable state

Company	Delivery	Additional Information
Acelis - preferred	Patient Home: Yes, doing virtual training	Estimated Time: Before COVID-19~1
	for patients (If patient does not have	week. Current timeframe ~3-5 weeks
(877) 262-4669	technology, sending the patient a tablet	
	with a pre-paid box for return)	Frequency requirement: new patient
Website		starts at least 2x/month, can go to
Provider Form	Clinic Staff Training: No	monthly (with a new prescription sent)
Roche - preferred	Patient Home: Yes, doing virtual training if	Estimated Time: Before COVID-19 ~2-3
	patient has FaceTime or GoogleDuo	week. Current timeframe more variable
1 (800) 780-0675		
	Clinic Staff Training: Yes, if Roche trained	Frequency requirement: at least
Website	clinic representative available	2x/month
Physician Order Form		
Patient Authorization Form		
Remote Cardiac Services	Patient Home: Yes, doing in home and	Estimated Time: Currently 3-5 days for
	virtual training via telephone or FaceTime	insurance to be verified, will contact the
1 (800) 876-1010	·····	patient with out of pocket cost, then
	Clinic Staff Training: No. Patient can bring	shipped with same day shipping (1-2
Website	monitor shipped to home for in office	days). Total ~ 2 weeks
Prescription Form	training. Provider has to fill out a form	
	stating they did the training	Frequency requirement: must test on a
		weekly basis
mdINR	Patient home: Yes, doing in home or	Estimated Time: Ships out of New York,
	virtual	time estimate not available
(855) 431-5350		
	Clinic Training: Only for specific patients	Frequency requirement: must test on a
Website	(if insurance will not pay for home	weekly basis
Physician Order Form	training)	
Patient Order Form		